# NCT03937635 (NCT03937635)

> Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03937635
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Smoldering Plasma Cell Myeloma
- Interventions: Daratumumab; Dexamethasone; Lenalidomide; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 288
- Primary outcome: Overall survival (OS)
- Primary outcome: Functional Assessment of Cancer Therapy-General (FACT-G) score

## Commentary we found

- X threads: 245

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03937635

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03937635", "email": "<work email>"}; the inbox owner confirms by the emailed link.